Scarica l'app Stockscreener
0.013
6.56%
0.0008
Precedente Chiudi:
$0.0122
Aprire:
$0.013
Volume 24 ore:
3,556
Relative Volume:
0.06
Capitalizzazione di mercato:
$N/A
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+8.33%
1M Prestazione:
-9.72%
6M Prestazione:
-67.42%
1 anno Prestazione:
-76.41%
Intervallo 1D:
$0.0118
$0.0131
Intervallo di 1 settimana:
$0.011
$0.025
Portata 52W:
$0.005
$0.10
Nls Pharmaceutics Ag Stock (NLSPW) Company Profile
Nome
Nls Pharmaceutics Ag
Settore
Industria
Telefono
41 44 512 21 50
Indirizzo
The Circle 6, Zurich
Confronta NLSPW con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NLSPW
Nls Pharmaceutics Ag
|
0.0131 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.08 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
706.50 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
666.58 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.46 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.66 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nls Pharmaceutics Ag Borsa (NLSPW) Ultime notizie
Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews
Dow Edges Lower; Exxon Mobil Earnings Top Views - Benzinga
NLS Pharmaceutics Says Kadimastem Shareholders Approve Merger With NLS; Shares Rise - Marketscreener.com
Nasdaq Jumps Over 150 Points; Apple Posts Upbeat Earnings - Benzinga
NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice - ACCESS Newswire
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics -January 31, 2025 at 07:31 am EST - Marketscreener.com
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements - ACCESS Newswire
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Marketscreener.com
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Benzinga
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform - ACCESS Newswire
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - ACCESS Newswire
NLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual Decline - MSN
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS - Marketscreener.com
SEC Form 425 filed by NLS Pharmaceutics Ltd. - Quantisnow
Pre-market Movers: HSDT, PBM, MTEM, APTO... - RTTNews
Pre-market Movers: ONCO, EYEN, SGMO, VSTM... - RTTNews
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market S - Quantisnow
Head-To-Head Analysis: Atossa Therapeutics (NASDAQ:ATOS) & NLS Pharmaceutics (NASDAQ:NLSP) - Defense World
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - PR Newswire
NLS Pharmaceutics and Kadimastem eye January merger - Investing.com
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment - AccessWire
NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline By Investing.com - Investing.com South Africa
NLS Pharmaceutics Advances Revolutionary Type 1 Diabetes Treatment, Seeks FDA Pre-IND Meeting - StockTitan
NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline - Investing.com India
NLSP stock touches 52-week low at $1.81 amid market challenges - Investing.com Nigeria
NLS Pharmaceutics advances in narcolepsy treatment research - Investing.com India
NLS Pharmaceutics advances in narcolepsy treatment research By Investing.com - Investing.com UK
NLS Pharmaceutics CEO Issues Letter to Shareholders - AccessWire
NLS Pharmaceutics Secures $4.2M Funding, Reports Breakthrough in Narcolepsy Treatment Development - StockTitan
NLS Pharmaceutics AG announced that it expects to receive $0.999998 million in funding - Marketscreener.com
NLS Pharmaceutics sets terms for $1M private placement By Investing.com - Investing.com Australia
NLS Pharmaceutics sets terms for $1M private placement - Investing.com
NLS Pharmaceutics reports preclinical data supporting dual orexin receptor agonists - BioWorld Online
NLSP Stock Touches 52-Week Low at $2.98 Amid Market Challenges By Investing.com - Investing.com South Africa
NLS Pharmaceutics reveals promising preclinical data By Investing.com - Investing.com Nigeria
NLSP Stock Touches 52-Week Low at $2.98 Amid Market Challenges - Investing.com
NLS Pharmaceutics reveals promising preclinical data - Investing.com
NLS Pharmaceutics announces preclinical data on DOXA platform - TipRanks
NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders - AccessWire
NLS Pharmaceutics Reports Breakthrough in Sleep-Wake Drug Development | NLSPW Stock News - StockTitan
NLS Pharmaceutics Unveils Promising Narcolepsy Treatment - TipRanks
NLS Pharmaceutics highlights preclinical program for AEX-41, AEX-2 - TipRanks
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders - AccessWire
NLS Pharmaceutics Advances Novel Dual Orexin Drug Platform in Key Preclinical Study | NLSPW Stock News - StockTitan
NLS Pharmaceutics AG Announces Share Capital Expansion - TipRanks
NLSP stock touches 52-week low at $3.15 amid market challenges - Investing.com
500: Something went wrong - Investing.com India
Kadimastem Ltd. Faces Financial Uncertainty - TipRanks
NLS Pharmaceutics Announces Strategic Capital Restructuring - TipRanks
NLS and Kadimastem stocks soar following merger agreement - Yahoo Finance
Nls Pharmaceutics Ag Azioni (NLSPW) Dati Finanziari
Non sono disponibili dati finanziari per Nls Pharmaceutics Ag (NLSPW). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.72%
3.18%
Capitalizzazione:
|
Volume (24 ore):